Trends and determinants of prescription medication use for treatment of osteoporosis

American Journal of Health-System Pharmacy

Volumn 66, Issue 13, 2009, Pages 1191-1201

  Farley, Joel F ^a   Blalock, Susan J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Androgens; Bisphosphonates; Calcitonin; Epidemiology; Estrogen agonist antagonists; Estrogens; Osteoporosis; Parathyroid hormones; Progestins; Raloxifene; Steroids, cortico; Testosterone; Toxicity

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; ESTROGEN; IBANDRONIC ACID; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; TESTOSTERONE; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DISEASE PREDISPOSITION; EDUCATIONAL STATUS; FEMALE; HEALTH CARE; HEALTH STATUS; HORMONAL THERAPY; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; TREND STUDY; UNITED STATES; EPIDEMIOLOGY; MIDDLE AGED;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESTROGENS; FEMALE; GLUCOCORTICOIDS; HEALTH CARE SURVEYS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROGESTERONE; SMOKING; TESTOSTERONE; UNITED STATES;

EID: 70349260976     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080248     Document Type: Article

References (52)

1. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. www.nof.org/advocacy/prevalence. index.htm (accessed 2009 Jan 30).
2. Riggs B, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995; 17:505S-11S.
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359:1761-1767
4. Ray NF, Chan JK, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997; 12:24-35.
5. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum. 2001; 44:1496-1503
6. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290:1729-1738 (Pubitemid 37430623)
7. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-333
8. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291:1701-1712
9. Lee E, Wutoh AK, Xue Z et al. Osteoporosis management in a Medicaid population after the Women's Health Initiative study. J Womens Health (Larchmt). 2006; 15:155-161
10. Udell JA, Fischer MA, Brookhart MA et al. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res. 2006; 21:765-771
11. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535-1541
12. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:1809-1822 (Pubitemid 46698462)
13. Chesnut CH 3rd, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19:1241-1249
14. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:2077-2082
15. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282: 1344-1352
16. Liberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333:1437-1443
17. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344:333-340
18. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Inf. 1999; 9:461-468
19. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of rise-dronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Rise-dronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11:83-91.
20. National Osteoporosis Foundation. Clinicians guide to prevention and treatment of osteoporosis. www.nof.org/professionals/NOF-Clinicians-Guide.pdf (accessed 2008 May 18).
21. MacLean C, Newberry S, Maglione M et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148:197-213. (Pubitemid 351665507)
22. Cadarette SM, Katz JN, Brookhart MA et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008; 148:637-646
23. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282:637-645 [Erratum, JAMA. 1999; 282:2124.]
24. Vondracek SF, Hansen LB. Current approaches to the management of osteoporosis in men. Am J Health-Syst Pharm. 2004; 61:1801-1811 (Pubitemid 39481361)
25. Bahl S, Coates PS, Greenspan SL. The management of osteoporosis following hip fracture: have we improved our care? Osteoporos Int. 2003; 14:884-888
26. Cuddihy MT, Gabriel SE, Crowson CS et al. Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med. 2002; 162:421-426
27. Freedman KB, Kaplan FS, Bilker WB et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000; 82-A:1063-1070
28. Khan SA, De Geus C, Holroyd B et al. Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med. 2001; 161:1309-1312 (Pubitemid 32679581)
29. Follin SL, Black JN, McDermott MT. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy. 2003; 23:190-198
30. Brookhart MA, Avorn J, Katz JN et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007; 120:251-256 (Pubitemid 46341156)
31. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006; 38:922-8.
32. Kothawala P, Badamgarav E, Ryu S et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82:1493-1501
33. McCombs JS, Thiebaud P, McLaughlin-Miley C et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004; 48:271-287 (Pubitemid 38781153)
34. Rossini M, Bianchi G, Di Munno O et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006; 17:914-921 (Pubitemid 43781506)
35. Solomon DH, Finkelstein JS, Katz JN et al. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003; 115:398-400. (Pubitemid 37311258)
36. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. www.meps.ahrq.gov/mepsweb (accessed 2008 May 11).
37. Cohen SB. Design strategies and innovations in the Medical Expenditure Panel Survey. Med Care. 2003; 41(suppl 7):III5-III12.
38. Saag KG. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am J Med. 1997; 103:31S-9S.
39. Dequeker J, Westhovens R. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention. J Rheumatol. 1995; 22:1013-1019
40. Siris ES, Miller PD, Barrett-Connor E et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286:2815-2822
41. Pressman A, Forsyth B, Ettinger B et al. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int. 2001; 12:337-342 (Pubitemid 32606455)
42. Melton LJ 3rd, Atkinson EJ, O'Connor MK et al. Bone density and fracture risk in men. J Bone Miner Res. 1998; 13:1915-23.
43. Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int. 2000; 11:680-687 (Pubitemid 30786248)
44. Kellie SE, Brody JA. Sex-specific and race-specific hip fracture rates. Am J Public Health. 1990; 80:326-328
45. Center JR, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353:878-882
46. Farley JF, Cline RR, Gupta K. Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). Osteoporos Int. 2006; 17:395-404.
47. Gourlay ML, Callahan LF, Preisser JS et al. Osteoporosis preventive care in white and black women in community family medicine settings. South Med J. 2007; 100:677-682
48. Furstenberg AL, Mezey MD. Differences in outcome between black and white elderly hip fracture patients. J Chronic Dis. 1987; 40:931-938
49. Jacobsen SJ, Goldberg J, Miles TP et al. Race and sex differences in mortality following fracture of the hip. Am J Public Health. 1992; 82:1147-1150
50. Goode JV, Swiger K, Bluml BM. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis. J Am Pharm Assoc. 2004; 44:152-160
51. MacLaughlin EJ, MacLaughlin AA, Snella KA et al. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy. 2005; 25:379-386
52. Naunton M, Peterson GM, Jones G. Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother. 2006; 40:38-44. (Pubitemid 43221472)